Ischemic Preconditioning Alters the Epigenetic Profile of the Brain from Ischemic Intolerance to Ischemic Tolerance

被引:0
|
作者
John W. Thompson
Kunjan R. Dave
Juan I. Young
Miguel A. Perez-Pinzon
机构
[1] University of Miami,Cerebral Vascular Disease Research Laboratories, Department of Neurology, Miller School of Medicine
[2] University of Miami,John P. Hussman Institute for Human Genomics and Dr. John T. Macdonald Department of Human Genetics, Miller School of Medicine
来源
Neurotherapeutics | 2013年 / 10卷
关键词
Ischemic preconditioning; Stroke; Histone acetylation; DNA methylation; microRNA;
D O I
暂无
中图分类号
学科分类号
摘要
Ischemic preconditioning is an innate neuroprotective mechanism in which a sub-injurious ischemic exposure increases the brain’s ability to withstand a subsequent, normally injurious ischemic insult. Part of ischemic preconditioning neuroprotection stems from an epigenetic reprogramming of the brain to a phenotype of ischemic tolerance, which results in a gene expression profile different from that observed in the non-injured and ischemia-injured brains. Such neuroprotective reprograming, activated by ischemic preconditioning, requires specific changes in DNA accessibility coordinated with activation of transcriptional activator and repressor proteins, which allows for expression of specific neuroprotective proteins despite a general repression of gene expression. In this review we examine the effects of injurious ischemia and ischemic preconditioning on the regulation of DNA methylation, histone post-translational modifications, and non-coding RNA expression. There is increasing interest in the role of epigenetics in disease pathobiology, and whether and how pharmacological manipulation of epigenetic processes may allow for ischemic neuroprotection. Therefore, a better understanding of the epigenomic determinants underlying the modulation of gene expression that lead to ischemic tolerance or cell death offers the promise of novel neuroprotective therapies that target global reprograming of genomic activity versus individual cellular signaling pathways.
引用
收藏
页码:789 / 797
页数:8
相关论文
共 50 条
  • [1] Ischemic Preconditioning Alters the Epigenetic Profile of the Brain from Ischemic Intolerance to Ischemic Tolerance
    Thompson, John W.
    Dave, Kunjan R.
    Young, Juan I.
    Perez-Pinzon, Miguel A.
    NEUROTHERAPEUTICS, 2013, 10 (04) : 789 - 797
  • [2] EXERCISE PRECONDITIONING AND BRAIN ISCHEMIC TOLERANCE
    Zhang, F.
    Wu, Y.
    Jia, J.
    NEUROSCIENCE, 2011, 177 : 170 - 176
  • [3] Ischemic preconditioning and tolerance in human brain
    Cheung, RTF
    STROKE, 2000, 31 (09) : 2272 - 2272
  • [4] Ischemic preconditioning in the brain
    Davis, Daniel P.
    Patel, Piyush M.
    CURRENT OPINION IN ANESTHESIOLOGY, 2003, 16 (05) : 447 - 452
  • [5] Ischemic preconditioning in the brain
    Baker, A
    CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE, 2004, 51 (03): : 201 - 205
  • [6] Ischemic preconditioning as induction of ischemic tolerance after transient ischemic attacks in human brain: its clinical relevance
    Schaller, B
    NEUROSCIENCE LETTERS, 2005, 377 (03) : 206 - 211
  • [7] Ischemic preconditioning protects against ischemic brain injury
    Xiao-meng Ma
    Mei Liu
    Ying-ying Liu
    Li-li Ma
    Ying Jiang
    Xiao-hong Chen
    NeuralRegenerationResearch, 2016, 11 (05) : 765 - 770
  • [8] Ischemic preconditioning protects against ischemic brain injury
    Ma, Xiao-meng
    Liu, Mei
    Liu, Ying-ying
    Ma, Li-li
    Jiang, Ying
    Chen, Xiao-hong
    NEURAL REGENERATION RESEARCH, 2016, 11 (05) : 765 - 770
  • [9] Limb ischemic preconditioning induces brain ischemic tolerance via p38 MAPK
    Sun, Xiao-Cai
    Li, Wen-Bin
    Li, Qing-Jun
    Zhang, Min
    Xian, Xiao-Hui
    Qi, Jie
    Jin, Rui-Li
    Li, Shu-Qin
    BRAIN RESEARCH, 2006, 1084 : 165 - 174
  • [10] Resveratrol and ischemic preconditioning in the brain
    Raval, Ami P.
    Lin, Hung Wen
    Dave, Kunjan R.
    DeFazio, R. Anthony
    Della Morte, David
    Kim, Eun Joo
    Perez-Pinzon, Miguel A.
    CURRENT MEDICINAL CHEMISTRY, 2008, 15 (15) : 1545 - 1551